Topical resiquimod effective for early-stage cutaneous T-cell lymphoma

Topical resiquimod was effective and well tolerated in patients with early-stage cutaneous T-cell lymphoma (CTCL), in some cases inducing regression in both treated and untreated lesions, according to researchers. The mean number of prior unsuccessful therapies among the patients was 6, yet the...
Source: Skin and Allergy News - Category: Dermatology Source Type: news